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It has been shown that certain chemokine receptor polymorphisms may correspond to certain complications after organ
transplantation. Ischemic-type biliary lesion (ITBL) encounters for major morbidity and mortality in liver transplant recipients.
So far, the exact cause for ITBL remains unclear. Certain risk factors for the development of ITBL like donor age and cold
ischemic time are well described. In a previous study, a 32-nucleotide deletion of the chemokine receptor-5Δ32 (CCR-5Δ32)
was strongly associated with the incidence of ITBL in adult liver transplantation. This study re-evaluates the association of CCR-
5Δ32 gene polymorphism and the incidence of ITBL. 169 patients were included into this retrospective analysis. 134 patients were
homozygous for wild-type CCR-5, 33 patients heterozygous, and 2 patients were homozygous for CCR-5Δ32 mutation. There
were no major diﬀerences in donor or recipients demographics. No association was found between CCR-5Δ32 mutation and the
development of ITBL. We conclude that CCR-5Δ32 is no risk factor for the development of ITBL in our patient cohort.
Copyright © 2009 Christoph Heidenhain et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The terms “nonanastomotic biliary strictures”, “intrahepatic
biliary strictures”, or “ischemic-type biliary lesion” (ITBL)
are often used as synonyms for hilar or intrahepatic diﬀuse
bile duct strictures, necrosis, ecstasies, or dilatations (see
Figure 1)[ 1, 2]. The reported incidence of ITBL after OLT
varies between 1.4% and 20% [3–5]. Some centers report
even higher incidence [6]. Patient and graft survival after
the diagnosis of ITBL are signiﬁcantly reduced [7]. ITBL is
the third most common reason for hepatic retransplantation
[8]. This complication encounters for major morbidity and
mortality, creates high costs, and aggravates organ shortage
[7, 8].
1The exact cause of ITBL still remains unclear. Only
relevant risk factors are described. However, data about risk
factors for the development of ITBL are inconsistent. A
recent study on 1113 liver transplant patients showed no
relevant donor or recipient risk factor of ITBL [5]. There
are only two studies evaluating the impact of chemokine
receptors (CCR) on the development of ITBL [6, 9]. In
Moench’s study on 146 OLT patients CCR-5Δ32 mutation
was evaluated and correlated with a signiﬁcant increased
incidence of ITBL [6]. A recent study on 137 pediatric liver
transplants failed to show an association between CCR-
5Δ32 and biliary complications [9]. CCR-5Δ32 is a single
base-pair deletion of CCR-5 that leads to a nonfunctional
receptor [10]. The clinical impact of this mutation was
ﬁrst described for homozygous CCR-5Δ32 Caucasians being
highly resistant to HIV-1 infection [11]. If there was an
immunological cause for ITBL, a nonfunctional CCR might
be relevant for this complication. Homozygous CCR-5Δ32
patients showed a signiﬁcant increased renal allograft sur-
vival [12]. Experimental studies correlated a nonfunctional
CCR-5 with less acute rejection episodes in lung [13], heart
[14] and islet cell transplantation [15].2 Journal of Transplantation
02
Figure 1: Intrahepatic presentation of ischemic-type biliary lesion
six months after hepatic transplantation for chronic hepatitis B-
associated liver cirrhosis. The patient’s hepatic artery is patent, and
thereisnootherknowncauseforthedestructionoftheintrahepatic
biliary tract.
The aim of this study was to re-examine a correlation of
CCR-5Δ32 genotype with the susceptibility of ITBL within
our patients.
2. Patientsand Methods
169 liver transplant patients were analyzed retrospectively.
All patients were transplanted at the transplant center of the
HumboldtUniversityofBerlinbetween03/2002and03/2005
and were included during routine Follow-up examination.
Follow-upperiodwas24monthsminimum.11patientswith
the established diagnosis of ITBL, that were transplanted
earlier than 03/2001, were selectively included into this study
due to the low incidence of ITBL of only 4.0% within
our patients. The diagnosis of ITBL was made within the
ﬁrst year after transplantation in 82% of the patients. The
followingdemographicdatawereextractedfromthehospital
records and evaluated: age, gender, underlying liver disease,
blood group, Child-Pugh score (CPS), model for end stage
liver disease score (MELD score), initial immunosuppres-
sion, cytomegalovirus infection (CMV), HLA match, donor
age and gender, donor serum sodium, cause of brain death
andlength of stay onintensive careunit (ICU) prior to organ
harvesting. 154 patients received a cadaver graft, 15 patients
received a graft from a living donor. Altogether, 19 split-liver
transplantation were included. The local ethic committee
approved the study. Written informed consent was obtained
from all patients before blood was taken for DNA analysis.
3. Deﬁnition of ITBL
ITBL was deﬁned as nonanastomotic intra- or extrahepatic
biliary strictures without any history of hepatic artery
complications, ABO, incompatibility or other known causes
ofbileductdamages.Inallcasespatencyofthehepaticartery
was proved by Doppler ultrasound, computer tomography
based angiography or conventional angiography. Recurrence
of primary biliary cirrhosis (PBC) or primary sclerosing
cholangitis (PSC) and vanishing bile duct syndrome were
ruled out in all cases by liver biopsy. Diagnosis of ITBL was
always established with endoscopic retrograde cholangiogra-
phy or percutaneous transhepatic cholangiography.
4.GenotypeAnalysis
All genotype analyses were performed at the Johannes
Gutenberg University of Mainz, Department of Transplanta-
tion Surgery. For analysis of the CCR-5 genotype, genomic
DNA was prepared from 200µL peripheral blood using
the QIAamp DNA blood kit (Qiagen, Cologne, Germany).
2.5µL of DNA were ampliﬁed by PCR using the fol-
lowing CCR-5 speciﬁc primers: CCR-sense, 5 -CAAAAA-
GAAGGTCTTCATTACACC-3  and CCR-5-antisense, 5 -
CCTGTGCCTCTTCTTCTCATTTCG-3 .T h eP C Rm i x t u r e
was composed of 2.5µL1 0xP C Rb u ﬀer (Roche Molecular
Systems, Mannheim, Germany), 0.5 µL of 12.5mmol/L
dNTP (PeqLab, Erlangen, Germany,), 2.5µLo fe a c hs e n s e
and antisense primer (10µmol/L), and 1.25U AmpliTag
DNA polymerase (Roche Molecular Systems) in a total
volume of 25µL .F o r t yP C Rc y c l e sw e r er u no naG e n i u s
thermocycler (Techne, Cambridge, UK), using the following
temperature proﬁle: initial denaturation, 94◦C3m i n u t e s ;
ampliﬁcation, 94◦C1m i n u t e ,6 4 ◦C 1 minute, and, 72◦C1
minute(40cycles);terminalelongation,72◦C9minutes.The
sizeofthewild-typeproductwas189basepairs(bp),andthe
CCR-5Δ32 allele yielded a product of 157bp. PCR products
were analyzed by 2% agarose gel electrophoresis.
5.StatisticalAnalysis
All statistical calculations were performed in SPSS 11.3
(SPSS Inc., Chicago, USA). Data are given as mean values
± standard deviation. Descriptive statistics were used to
summarize the donor and recipients characteristics. For
independent variables, cross tabulations and chi-square tests
were performed. Nonparametric variables were evaluated
with Fisher’s exact test, and asymptotic signiﬁcance was
calculated.
All of the tests performed were two-sided. P-values of
P <.05wereconsideredasstatisticallysigniﬁcant.Allcalcula-
tions were performed in association with the Department of
Biometrical Medicine of the Humboldt University of Berlin.
6. Results
6.1.PatientCharacteristicsandGenotypeDistribution. Atotal
number of 169 liver transplant recipients were available for
genotyping and complete data analysis. Gender and age
were equally distributed between wild-type group (wt/wt)
and heterozygous CCR-5Δ32 group (wt/Δ32). Patients in
the homozygous group (Δ32/Δ32) were female and male.
The observed genotype frequency was as expected assessed
by Hardy-Weinberg equilibrium in the study population.
There were no diﬀerences between wt/wt group and wt/Δ32Journal of Transplantation 3
Table 1: Recipient characteristics. MELD: model for end-stage liver disease; CPS: Child-Pugh score; BG: recipients blood group; wt/wt:
wild-typeCCR-5;wt/Δ32:heterozygousCCR-5Δ32;Δ32/Δ32:homozygousCCR-5Δ32;CMV:cytomegalovirus;OKT-3:monoclonalmurine
anti-CD-3 antibody.
Recipient characteristics
Variables wt/wt wt/Δ32 Δ32/Δ32 P-value
n (169) 134 (79.3%) 33 (19.5%) 2 (1.2%)
Recipient gender
Male 89 (66.4%) 22 (66.7%) — .137
Female 45 (33.6%) 11 (33.3%) 2 (100%)
Mean recipient age (years) 50.2 ±10.34 9 .8 ±9.94 7 .5 ±17.7 .443
MELD Score (mean ± SD) 17.2 ±8.7 17.9 ± 9 — .960
CPS A 13 (11.8%) 4 (16%) 1 (50%) .487
CPS B 60 (54.5%) 13 (52%) 1 (50%)
CPS C 37 (33.7%) 8 (32%) —
BG A 52 (39.1%) 10 (30.3%) 1 (50%) .823
BG B 19 (14.3%) 4 (12.1%) —
BG AB 15 (11.3%) 3 (9.1%) —
BG O 47 (35.3%) 16 (48.5%) 1 (50%)
Hepatitis B-related cirrhosis 16 (11.9%) 3 (9.1%) — .918
Hepatitis C-related cirrhosis 21 (15.7%) 6 (18.2%) —
Hepatocellular carcinoma 19 (14.2%) 4 (12.1%) —
Primary biliary cirrhosis 6 (4.5%) — 2 (100%)
Primary sclerosing cholangitis 4 (3%) 2 (6.1%) —
Acute liver failure 4 (3%) 3 (9.1%) —
Autoimmune hepatitis 2 (1.5%) — —
Metabolic liver diseases 2 (1.5%) 3 (9.1%) —
Alcohol-induced cirrhosis 41 (30.6%) 9 (27.3%) —
Retransplantation 4 (3%) 1 (3%) —
Others 15 (11.2%) 2 (6.1%) —
Cold ischemic time (minutes) 533 ± 144 582 ± 202 633 .806
Initial Immunosuppression
Tacrolimus 110 (82.6%) 28 (84.8%) 2 (100%) .824
Cyclosporine A 23 (17.2%) 4 (12.1%) —
others 1 (0.7%) 1 (3.0%) —
HLA match
0 match 24 (26.4%) 6 (27.3%) 2 (100%) .448
1 match 40 (44.0%) 8 (36.4%) —
2 matches 21 (23.1%) 5 (19.2%) —
3 matches 5 (5.5%) 2 (9.1%) —
4–6 matches 1 (1.1%) 1 (4.5%) —
CMV Infection
postitve 43 (32.1%) 12 (36.4%) 2 (100%) .117
negative 28 (20.9%) 2 (6.1%) —
unknown 63 (47.0%) 19 (57.6%) —
group regarding to CPS score, MELD score or blood group
(Table 1).
There were no statistical signiﬁcant diﬀerences in the
composition of underlying liver disease of group wt/wt and
wt/Δ32. Both patients with Δ32/Δ32 had primary biliary
cirrhosis as underlying liver disease.
Initial immunosuppression was tacrolimus based in
82.6% in the wt/wt group compared to 84.8% in the wt/Δ324 Journal of Transplantation
Table 2: Donor characteristics. ICU: intensive care unit; wt/wt: wild-type CCR-5; wt/Δ32: heterozygous CCR-5Δ32; Δ32/Δ32: homozygous
CCR-5Δ32.
Donor characteristics
wt wt/Δ32 Δ32/Δ32 P-value
Donor age (years) 46.5 ±17.24 8 .5 ±16.53 5 .7 ±11.2 .663
Donor gender
Male 76 (56.7%) 20 (60.6%) 1 (50%) .901
Female 58 (43.3%) 13 (39.4%) 1 (50%)
Mean donor serum Na+ (mmol/L) 146.9 ±8.4 147.7 ±7.9 155,5 ± 27.5 .552
Cause of brain death
Subarachnoidal bleeding 75 (56%) 16 (48.5%) 1 (50%) .866
Trauma 31 (23.1%) 8 (24.2%) —
Intracerebral bleeding 1 (0.7%) 1 (0.6%) —
Hypoxia 3 (2.2%) — —
Brain tumor 1 (0.7%) — —
Cardiac infarction 1 (0.7%) — —
Cerebral infarction 10 (7.5%) 3 (9.1%) —
others 12 (9%) 5 (15.2%) 1 (50%)
Stay on the ICU prior to Organ harvesting (days) 4.3 ±4.74 .7 ±3.8 7.0 .564
Table 3: Events after transplantation. wt/wt: wild type CCR-5; wt/Δ32: heterozygous CCR-5Δ32; Δ32/Δ32: homozygous CCR-5Δ32; ITBL:
ischemic-type biliary lesion; Re-OLT: retransplantation.
Incidence of ITBL or Re-transplantation
Events wt/wt wt/Δ32 Δ32/Δ32 P-value
n 134 33 2
No ITBL 119 (88.8%) 29 (87.9%) 2(100%) .870
ITBL 15 (11.2%) 4 (12.1%)
No Re-OLTx 130 (97%) 32 (97%) 2 (100%) .970
Re-OLTx 3(3%) 1 (3%) —
group. Likewise, cold ischemic time and HLA match showed
no diﬀerences between groups. Both homozygous Δ32
patientshadzeroHLAmatch.CMVinfectionthatdemanded
ganciclovir treatment was present in approximately 30%
in the wt/wt and wt/Δ32 group and in both homozygous
patients.
6.2. Donor Characteristics. There were no diﬀerences
between group regarding donor age or gender. Donors
of group Δ32/Δ32 were younger (35.7 years versus
46.5 years and 48.5 years). Mean donor serum sodium
was 146.9mmol/L in the wt/wt group compared with
147.7mmol/L in the wt/Δ32 group and 155.5mmol/L in the
Δ32/Δ32 group. Data of causes of brain death and length
of stay on the ICU prior to organ harvesting are shown in
Table 2.
6.3. Incidence ITBL and Rate of Retransplantation. Incidence
of ITBL was 11.2% in this study due to the selection of
patients with ITBL that were additionally included into this
evaluation. Homozygous Δ32 patients developed no ITBL
compared to 11.2% and 12.1% of homozygous wild-type
patients and heterozygous patients, respectively. The rate
of retransplantation was 3.0% in both wt/wt and wt/Δ32
group (see Table 3). Retransplantation of the heterozygous
patient was indicated due to chronic ductopenic rejection
following OLT for PSC. In the wt/wt group, the indications
for retransplantation were INF, cryptogenic recirrhosis, and
ITBL.
7. Discussion
The problem of genetic association studies and complex
clinical syndromes or diseases must be addressed. One can
always question the usefulness of these studies that are
often even small in sample size. Most of these studies
are statistically underpowered. On the other side, it seems
important to undertake replication studies for reported
associations between genetic polymorphisms and diseases,
especially in diseases of major clinical importance.
In this study, the distribution of heterozygous Δ32
and homozygous Δ32 mutation was very consistent with
the published data of the global distribution of this geneJournal of Transplantation 5
polymorphism [10, 16]. Heterozygous and homozygous
genotypes occur in Caucasian population in 15%–20% and
1%, respectively [16]. Heterozygous individuals show no
abnormal receptor function compared with wt/wt individ-
uals. All examined donor and recipient factors showed no
statistical diﬀerences between groups. This seems important
due to the small number of patients included in this study
and the possible bias by including selected patients with the
diagnosis of ITBL into the study cohort.
Despite increasing success rates in clinical OLT over
the past decades, ITBL remains a major cause for recipient
morbidity and mortality [1–5]. This single complication
creates enormous costs and aggravates organ shortage. Up
till today, only risk factors for ITBL could be identiﬁed in
various clinical studies. The length of cold ischemic time
was correlated with the development of ITBL [1–4]. Donor
age was found to be a signiﬁcant risk factor for ITBL.
Other studies were not able to show these correlations [5].
Immunological causes seem to play only a minor role in
the pathogenesis of ITBL. Moench et al. described a single
base-pair deletion in the coding region of the chemokine
receptor-5Δ32, CCR-5Δ32, to be a signiﬁcant risk factor for
the development of ITBL. In Moench’s study on 146 OLT
patients CCR-5Δ32 was a signiﬁcant risk factor for ITBL
(incidence of ITBL in CCR-5Δ32 patients was 30% versus
11.7% in CCR-5 wild-type patients) and was correlated
with a decreased survival rate after OLT. The overall ITBL
rate was 15% [6]. The diﬀerent incidence of ITBL of the
study by Moench and this study may be a reason for the
diﬀerent ﬁndings, even though both investigators used the
same deﬁnition of ITBL. Donors were younger in this study
with 38.2 ± 16 (non-ITBL patients) and 42.9 ± 17 (ITBL)
versus 46 ± 14 (non-ITBL) and 52 ± 14 (ITBL) in Moench’s
study. However, cold ischemic time was shorter in Moench’s
investigation (564 minutes (ITBL) and 538 minutes (non-
ITBL) versus 637 minutes (ITBL) and 558 minutes (non-
ITBL)). The use of arterial back table perfusion was also
routinely done for all organs that were harvested by a
team of our own. Fischer-Maas et al. analyzed CCR-5Δ32
polymorphism in 137 pediatric patients but showed no
correlation with biliary complications [9]. The incidence
of ITBL varies between 1.4% and 20% according to the
literature, which might be a problem of diﬀerent deﬁnition
of this disease [3–5]. The rate of ITBL in our OLT patients
(2100 patients between 1988 and 2004) is 4.0%. In the
presented study on 169 OLT patients the overall incidence
of ITBL was 11.7%, but only due to a selective inclusion of
patients with the established diagnosis of ITBL. This practice
of patient recruitment may be criticized, but we think it is
justiﬁed according to our low incidence of ITBL. Thus, it was
possible to investigate 19 patients with ITBL. ITBL rate in
CCR-5Δ32 patients was virtually equal to the one in CCR-
5 wild-type patients. No statistically signiﬁcant diﬀerences
regarding ITBL or retransplantation were observed.
Why would CCR-5Δ32 mutation promote the devel-
opment of ITBL? CCR-5Δ32 is a 32-base-pair deletion
within the coding region of CCR-5, which results in a
frame shift and generates a nonfunctional receptor [11].
Homozygous expression of CCR-5Δ32 is associated with
a reduced risk of asthma and with a reduced severity of
rheumatoid arthritis [17, 18], multiple sclerosis [19, 20], and
primary biliary cirrhosis (PBC) [21]. In other words, the
nonfunctional nature of CCR-5Δ32 protects the individual
from autoimmune diseases where CCR-5 seems to play a
central pathophysiological role. These data do not backup
the theory, that immunological risk factors are dominant in
thedevelopmentofITBL.Likewise,acorrelationofareduced
survival rate with CCR-5Δ32 would not be consistent to
the literature, where CCR-5Δ32 mutation is associated with
an increased survival in renal [12], lung [13], heart [14]
and islet cell transplantation [15]. In contrast to those
ﬁndings, CCR-5Δ32 is strongly associated with an increased
severity of PSC [22]. Patients suﬀering from PSC have been
described as carrying a higher risk for ITBL, with a reported
signiﬁcantly increased incidence of 15.8% to 25% [1, 8, 23].
Another study reported PSC as the only independent risk
factor for ITBL with an incidence of 31% compared with
9% of the control group [24]. However, the problem of
diﬀerentiation between ITBL and recurrence of PSC must be
addressed. Recurrence rates of 8.6% to 25% were described
for PSC after OLT [25–27]. The diagnose of recurrence of
PSC is based on cholangiographic ﬁndings of intrahepatic,
hilar and/or exrahepatic strictures, duct irregularities and on
the histopathological picture of ﬁbrous cholangitis and/or
ﬁbro-obliterative lesions with or without ductopenia, biliary
ﬁbrosis, or biliary cirrhosis [28]. Most of these ﬁndings are
neither pathognomonic for either recurrence of PSC nor
ITBL [29]. All patients with ITBL in this study underwent
percutaneous liver biopsy, and our pathologists ruled out
PSC recurrence. There remains a diagnostic uncertainty.
Since two of three studies failed to show an association
between ITBL and CCR-5Δ32 gene polymorphism, a general
recommendation for screening of OLT patients for CCR-
5Δ32 does not seem to be justiﬁed.
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